Literature DB >> 15118612

Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays.

Andrew Berchuck1, Edwin S Iversen, Johnathan M Lancaster, Holly K Dressman, Mike West, Joseph R Nevins, Jeffrey R Marks.   

Abstract

OBJECTIVE: The purpose of this study was to define gene expression patterns that are associated with the optimal versus suboptimal debulking of advanced-stage serous ovarian cancers. STUDY
DESIGN: RNA from 44 advanced serous ovarian cancers (19 optimal, 25 suboptimal) was evaluated with microarrays that contain >22,000 genes. Genes were screened on the basis of their association with debulking status to obtain the top 120 differentially expressed genes. These genes were then used to develop a predictive model for debulking status, which was subjected to out-of-sample cross validation.
RESULTS: We found that patterns of expression of 32 genes can distinguish between optimal and suboptimal debulking with 72.7% predictive accuracy. An analysis of the data that were based on clusters of co-ordinately expressed genes resulted in only a marginal improvement in predictive accuracy (75%).
CONCLUSION: These data support the hypothesis that favorable survival that is associated with optimal debulking of advanced ovarian cancers is due to, at least in part, the underlying biologic characteristics of these cancers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15118612     DOI: 10.1016/j.ajog.2004.02.005

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  26 in total

1.  Analysis of microarray experiments of gene expression profiling.

Authors:  Adi L Tarca; Roberto Romero; Sorin Draghici
Journal:  Am J Obstet Gynecol       Date:  2006-08       Impact factor: 8.661

2.  Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182.

Authors:  Neil S Horowitz; Austin Miller; Bunja Rungruang; Scott D Richard; Noah Rodriguez; Michael A Bookman; Chad A Hamilton; Thomas C Krivak; G Larry Maxwell
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

3.  Regulation of the metastasis suppressor gene MKK4 in ovarian cancer.

Authors:  Monique A Spillman; Judith Lacy; Susan K Murphy; Regina S Whitaker; Lisa Grace; Vanessa Teaberry; Jeffrey R Marks; Andrew Berchuck
Journal:  Gynecol Oncol       Date:  2007-02-05       Impact factor: 5.482

Review 4.  Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment.

Authors:  Analisa DiFeo; Goutham Narla; John A Martignetti
Journal:  Mt Sinai J Med       Date:  2009-12

5.  Surgical debulking of ovarian cancer: what difference does it make?

Authors:  John O Schorge; Christopher McCann; Marcela G Del Carmen
Journal:  Rev Obstet Gynecol       Date:  2010

6.  The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study.

Authors:  Chad A Hamilton; Austin Miller; Caela Miller; Thomas C Krivak; John H Farley; Mildred R Chernofsky; Michael P Stany; G Scott Rose; Maurie Markman; Robert F Ozols; Deborah K Armstrong; G Larry Maxwell
Journal:  Gynecol Oncol       Date:  2011-06-17       Impact factor: 5.482

7.  Peritoneal carcinosis of ovarian origin.

Authors:  Anna Fagotti; Valerio Gallotta; Federico Romano; Francesco Fanfani; Cristiano Rossitto; Angelica Naldini; Massimo Vigliotta; Giovanni Scambia
Journal:  World J Gastrointest Oncol       Date:  2010-02-15

Review 8.  Proteomics of ovarian cancer: functional insights and clinical applications.

Authors:  Mohamed A Elzek; Karin D Rodland
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

9.  The use of CT findings to predict extent of tumor at primary surgery for ovarian cancer.

Authors:  Gretchen Glaser; Michelle Torres; Bohyun Kim; Giovanni Aletti; Amy Weaver; Andrea Mariani; Lynn Hartmann; William Cliby
Journal:  Gynecol Oncol       Date:  2013-05-11       Impact factor: 5.482

10.  Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples.

Authors:  Markus Riester; Wei Wei; Levi Waldron; Aedin C Culhane; Lorenzo Trippa; Esther Oliva; Sung-Hoon Kim; Franziska Michor; Curtis Huttenhower; Giovanni Parmigiani; Michael J Birrer
Journal:  J Natl Cancer Inst       Date:  2014-04-03       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.